Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism
- PMID: 15003833
- DOI: 10.1016/j.regpep.2003.12.012
Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism
Abstract
The corticotropin-releasing factor (CRF) type 1 receptors (CRF(1)) from human (hCRF(1)) and Xenopus (xCRF(1)) differ from one another by their agonist- and antagonist-binding preference. While the agonist-binding site of the xCRF(1) receptor has been mapped, the amino acids that mediate binding of the potent peptide antagonist astressin are unknown. By constructing receptor chimeras followed by site-directed mutagenesis, the astressin-binding site of the xCRF(1) receptor was located between residues 76 and 83. This region partially overlaps with the agonist-selective domain of the xCRF(1) receptor (residues 76-89). Mutagenesis of the amphibian residues Gln(76), Gly(81) and Val(83) to the human sequence (Arg(76)Asn(81)Gly(83)) generated a receptor mutant that bound astressin with even higher affinity than the native hCRF(1) receptor. An amino acid doublet (Glu(70)Tyr(71)) that is conserved in the xCRF(1) and hCRF(2(a)) receptor after incorporation into the hCRF(1) receptor sequence was found to facilitate antagonist binding up to 15-fold higher. In agreement with the binding data, astressin was a more potent functional antagonist at receptors expressing the Glu(70)Tyr(71) motif. These data show that the agonist- and antagonist-binding sites of the hCRF(1) receptor partially overlap and that two amino acids within the N terminus of the hCRF(1) receptor negatively influence binding and functional antagonism of astressin.
Similar articles
-
Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.J Pharmacol Exp Ther. 2001 Jan;296(1):113-20. J Pharmacol Exp Ther. 2001. PMID: 11123370
-
Five amino acids of the Xenopus laevis CRF (corticotropin-releasing factor) type 2 receptor mediate differential binding of CRF ligands in comparison with its human counterpart.Mol Pharmacol. 2002 May;61(5):1132-9. doi: 10.1124/mol.61.5.1132. Mol Pharmacol. 2002. PMID: 11961131
-
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.Biochemistry. 2004 Apr 6;43(13):3996-4011. doi: 10.1021/bi036110a. Biochemistry. 2004. PMID: 15049707
-
Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.Front Neuroendocrinol. 1995 Oct;16(4):362-82. doi: 10.1006/frne.1995.1013. Front Neuroendocrinol. 1995. PMID: 8557170 Review.
-
Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors.Peptides. 2004 Oct;25(10):1689-701. doi: 10.1016/j.peptides.2004.03.027. Peptides. 2004. PMID: 15476936 Review.
Cited by
-
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.CNS Neurol Disord Drug Targets. 2006 Aug;5(4):453-79. doi: 10.2174/187152706777950684. CNS Neurol Disord Drug Targets. 2006. PMID: 16918397 Free PMC article. Review.
-
NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor.Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12836-41. doi: 10.1073/pnas.0404702101. Epub 2004 Aug 23. Proc Natl Acad Sci U S A. 2004. PMID: 15326300 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases